Brief note on Ariad Pharmaceuticals going into the ASH meeting, Dec 10-13

Brief note on Ariad Pharmaceuticals going into the ASH meeting, Dec 10-13

(As published on Seeking Alpha on Nov 3 2011, click here to read the post and additional comments)

Ariad Pharmaceuticals’ $1.5bn market cap is mainly driven by two drugs in advanced clinical stages: ridaforolimus for soft tissue and bone sarcoma and ponatinib for chronic myeloid leukemia (CML) and Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL). The former is partnered with Merck and presented top-line results of the phase III SUCCEED trial early this year. Merck is now on track to file an NDA later this year. Ariad also announced on August 18 that the EMA had accepted the MAA of the drug.

[Read more...]